SELLAS Life Sciences is a late-stage clinical biopharmaceutical company dedicated to pioneering innovative therapies for various cancer types. With a robust pipeline, the company is advancing its lead product, galinpepimut-S (GPS), an immunotherapeutic agent targeting the Wilms tumor 1 (WT1) protein, which plays a significant role in cancer progression. Additionally, SELLAS is developing SLS009, a selective cyclin-dependent kinase 9 (CDK9) inhibitor designed to target specific cancer mechanisms.

Founded by Dr. Angelos M. Stergiou, the company collaborates with prestigious institutions, including an exclusive partnership with Memorial Sloan Kettering Cancer Center (MSKCC) for galinpepimut-S, and collaborations with other biotechnology firms in China for broader access to their novel therapeutics.

SELLAS is committed to improving patient outcomes through groundbreaking research and clinical trials, aiming to address significant unmet medical needs in oncology. With a strong leadership team and a compelling vision, SELLAS Life Sciences is at the forefront of the biopharmaceutical landscape